Stem Cell Therapy in Autism Spectrum Disorder (ASD): What the Evidence Shows

Biological Rationale

• Neuroinflammation - Many children with ASD show elevated inflammatory markers. Mesenchymal stem cells (MSCs) are known to have immunomodulatory effects that could dampen this.
• Cerebral hypoperfusion - Reduced blood flow to certain brain regions is documented in ASD; stem cells may promote vascular repair.
• Synaptic and neuronal repair - Preclinical mouse models (BTBR autism model, valproic acid rat model) show that MSC transplantation reduces repetitive behaviors and improves social interaction, raising hippocampal BDNF levels.
• Gut-brain axis modulation - Emerging data suggest stem cells may alter gut microbiota, which is often dysregulated in ASD.

Types of Stem Cells Being Tested

What the Clinical Trials Show

Systematic Review & Meta-analysis (Villarreal-Martinez et al., 2022 - PMID 34515938)

• 11 trials, 461 patients
• CARS scale (autism severity): mean reduction of -9.08 points (95% CI -15.43 to -2.73) - a statistically significant improvement
• ABC scale (aberrant behavior): mean reduction of -11.97, but wide confidence intervals (not statistically convincing)
• VABS (adaptive behavior): small improvements across communication, socialization, and daily living domains
• No serious adverse events
• Caveat: Most trials were small, non-randomized, and had high risk of bias

RCT - Intrathecal autologous BMMNCs (Nguyen et al., 2025 - PMID 40442857)

• Phase II RCT, 50 children aged 3-7 years
• CT group: 2 intrathecal BMMNC infusions + education vs. education alone
• At 12 months: 48% reduction in most-severe DSM-5 classification in CT group vs. 8% in controls (p=0.004)
• CARS scores dropped -5.9 points (CT) vs. -1.5 points (controls) - statistically significant
• VABS-II improved 8.5 points vs. 1.4 points
• This is currently the strongest positive RCT published

RCT - Intrathecal autologous BMMSCs (Sharifzadeh et al., 2021 - PMID 33150703)

• 32 children, 5-15 years
• Primary outcomes (CARS, GARS-II): no significant difference between groups at 12 months
• Only CGI-Severity showed a significant group-time interaction
• Conclusion: "safe and feasible, but limited clinical efficacy"

Phase II RCT - Cord blood (Dawson et al., Duke University, 2020)

• 25 children with ASD received autologous cord blood
• No serious adverse events
• Showed improvements in some behavioral measures, but did not meet primary endpoints in the placebo-controlled phase

Key Limitations of the Current Evidence

1. Small sample sizes - Most trials have fewer than 50 participants
2. Open-label designs - Several lack proper blinding, which inflates apparent benefits
3. Short follow-up - Longest follow-up is ~12 months; durability is unknown
4. Heterogeneous ASD populations - ASD has enormous clinical variability; who responds is unclear
5. Publication bias - Negative trials may be underreported
6. No standard protocol - Cell types, doses, and routes differ widely across studies

Safety Profile

• Fever
• Headache
• Vomiting
• Transient hyperactivity or agitation
• No serious adverse events (tumor formation, infections, immune reactions) reported in published trials to date - though this is likely due to the small scale and short duration of trials

Regulatory & Guideline Status

• No regulatory body (FDA, EMA, MHRA) has approved any stem cell therapy for ASD
• The FDA has specifically warned against unproven stem cell clinics offering such treatments
• No major autism clinical guideline (NICE, AAP, IACAPAP) recommends stem cell therapy
• The therapy is classified as experimental/investigational worldwide

Bottom Line

• Some RCTs - especially the 2025 Vietnamese trial - show meaningful improvements in severity scores
• The 2022 meta-analysis shows a statistically significant effect on the CARS scale
• However, trial quality is generally low, sample sizes are small, and results are inconsistent
• The procedure carries procedural risks (bone marrow harvest, intrathecal injection)
• Families should be extremely cautious about commercial clinics offering this treatment, as the evidence does not yet support routine use and risks may outweigh unproven benefits